Single arm open-label study to evaluate efficacy and safety of low intensity extracorporeal shockwave therapy in prostate cancer patients with ED after radical prostatectomy

Single arm open-label study to evaluate efficacy and safety of low intensity extracorporeal shockwave therapy in prostate cancer patients with ED after radical prostatectomy - Study to evaluate efficacy and safety of low intensity extracorporeal shockwave therapy in patients with ED after radical prostatectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022514

Enrollment

Registered

2016-06-06

Start date

2016-06-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile dysfunction

Interventions

Low intensity extracorporeal shockwave therapy was applied to the penile shaft and crura.The duration of each low intensity extracorporeal shockwave therapy session was approximately 20 min, and each

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Prostate cancer patient is planned to the operation of radical prostatectomy. 2) Patient who is from 40 to 80 years old. 3) Patient had stable partnership of sexual intercourse over the three months until the radical prostatectomy. 4) Patient had the written consent of this study.

Exclusion criteria

Exclusion criteria: 1) Patient with spinal injury, chronic blood disease, and anatomic anomaly of penile vessels. 2) Patient with endocrine, mental or psychologic disease caused of erectile dysfunction. 3) Patients with past history of ischemic heart disease, cerebral hemorrhage, cerebral infarction and fetal arrhythmia, or who can not withdraw hemagogic drugs such as aspirin and warfarin. 4) Patients with cardiovascular disease prohibited to the sexual intercourse. 5) Patients have sexually transmitted infection and penile abscess. 6) Patients using nitrate drugs such as Nitroglycerin. 7) Patients judged not to appropriate to this study by the doctor in charge of this study.

Design outcomes

Primary

Measure	Time frame
To assess efficacy of low intensity extracorporeal shockwave therapy	—

Secondary

Measure	Time frame
To assess safety of low intensity extracorporeal shockwave therapy	—

Countries

Japan

Contacts

Public ContactShogo Inoue

Hiroshima University Hospital Urology

inosyogo@hiroshima-u.ac.jp082-257-5242

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026